Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
:SUPN
RESEARCH TOOLSreports
Holding SUPN?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.5Last Year’s EPS
0.88Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: 8.76%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in key products like Qelbree and GOCOVRI, substantial revenue increases, and positive advancements in the CNS pipeline. Despite challenges with declining sales in legacy products due to generic competition, the company demonstrated a strong cash position and raised its financial guidance, indicating a positive outlook.Company Guidance
During the Supernus Pharmaceuticals Q3 2024 earnings call, the company updated its financial guidance, raising its full-year 2024 total revenue expectation to a range of $630 million to $650 million, up from the previous guidance of $600 million to $625 million. This increase is driven by strong performance from key growth products, Qelbree and GOCOVRI, which contributed to a 26% increase in total revenues for the third quarter, excluding legacy products Trokendi XR and Oxtellar XR. Operating earnings on a GAAP basis for Q3 2024 saw a substantial rise to $40.9 million, compared to $8.1 million in the same period last year, highlighting a $32.8 million improvement. The guidance for full-year 2024 GAAP operating earnings is projected to range between $50 million and $65 million, with non-GAAP operating earnings expected to be between $150 million and $170 million. The company also reported a strong financial position with approximately $403.2 million in cash and marketable securities as of September 30, 2024, and no debt, offering significant financial flexibility for potential mergers and acquisitions.Strong Growth in Key Products
Qelbree showed a 19% growth in prescriptions and 68% growth in net sales, reaching an all-time high of 194,000 prescriptions and net sales of $62 million, representing an approximate annualized run rate of $250 million.
Revenue Increase
Total revenues excluding Trokendi XR and Oxtellar XR increased by 26% in the third quarter of 2024 compared to the same quarter last year.
Advancement in CNS Pipeline
The company announced positive data from its SPN-820 and SPN-817 studies, showing significant reductions in depression symptoms and seizure reduction, respectively.
Increase in Operating Earnings
Operating earnings on a GAAP basis for the third quarter increased by $32.8 million compared to the same quarter last year, driven primarily by an increase in net product sales.
Strong Cash Position
As of September 30, 2024, the company had approximately $403.2 million in cash, cash equivalents, and securities, showing significant financial flexibility.
Raised Financial Guidance
The company raised its financial guidance for full-year 2024, expecting total revenues to range from $630 million to $650 million, up from the previous range.
---
SUPN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SUPN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $34.70 | $34.74 | +0.12% |
| Aug 06, 2024 | $27.88 | $31.92 | +14.49% |
| May 08, 2024 | $31.30 | $30.00 | -4.15% |
| Feb 27, 2024 | $30.69 | $31.08 | +1.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Supernus Pharmaceuticals (SUPN) report earnings?
Supernus Pharmaceuticals (SUPN) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Supernus Pharmaceuticals (SUPN) earnings time?
Supernus Pharmaceuticals (SUPN) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SUPN EPS forecast?
SUPN EPS forecast for the fiscal quarter 2024 (Q4) is 0.5.
---